Exxon Mobil Corporation (XOM) or Total S.A. (ADR) (TOT)? This Supermajor Pays a Super Dividend

ConocoPhillips (NYSE:COP) spun off its downstream (refining) operations back in 2012, which now trades as Phillips 66 (check out the value in refining). The stock is now a standalone exploration and production company. ConocoPhillips is nearing completion of its three-year portfolio optimization plan and is also finishing up $9.6 billion in asset sales to help fund its $15 billion capital expenditure plan, pay dividends of $3.5 billion and $5 billion in stock buybacks.
ConocoPhillips’ $15 billion CapEx plan is one of the highest among Supermajors, but it will play a key role in its reserve replacement target of over 100%. Around 60% of CapEx is planned for North America liquids-rich plays, including its acreage portfolios in the Eagle Ford Shale, Permian Basin and Bakken Shale. ConocoPhillips pays a robust dividend yield of 4.6%, but still well below Total’s.
Don’t be fooled
Total pays the most robust dividend yield among all the Supermajors. What’s more is that it has a very reasonable payout ratio, at only 48%.
TOTAL BP Chevron Exxon Mobil ConocoPhillips
Dividend yield 6.0% 4.5% 3.1% 2.6% 4.6%
Dividend payout ratio 48% 54% 26% 23% 44%
The story gets even better. The stock is the cheapest among all Supermajors.
TOTAL BP Chevron Exxon Mobil ConocoPhillips
Forward P/E 7 8 10% 10.5 10
I like TOTAL S.A. (ADR) (NYSE:TOT)’s impressive dividend yield, especially when coupled with its “cheapness.” The stock should perform well on the back of a rebounding global economy and has over $21 billion in cash on hand, or $9.50 per share, giving it room to up its dividend over the interim.

The article This Supermajor Pays a Super Dividend originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Insider Monkey Small Cap Strategy  

Insider Monkey beat the market by 74 percentage points in 2.5 yearsOur beta is only 1.2 (download a FREE newsletter and see the details inside)

Billionaire Hedge Funds
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!